Business · 10/03/2014Updated: 10/17/2026 · 1 min read
Xanodyne Pharmaceuticals, Inc., et al. Withdraw Approval of Propoxyphene Drug Applications
Summary
The FDA is withdrawing approval of 8 new drug applications and 46 abbreviated new drug applications for prescription pain medications containing propoxyphene, following agreements from the applicants to waive their hearing rights.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →